SEOUL, South Korea, Feb. 27, 2026 /PRNewswire/ — RIMAN, a premium Korean skincare and wellness brand, announced its ICD Dermatology Line, featuring boosters, serums, and creams, has received the iF DESIGN AWARD 2026 in the Packaging Design category. The packaging reimagines RIMAN’s signature ingredient, Giant BYoungPool™ (Giant Centella Asiatica), in a minimalist and sophisticated form. The distinctive ‘Greenish Ivory’ color, inspired by Lava BYoungPool Water™, symbolizes clarity and vitality and reflects the synergy between Jeju Lava Energy Water and Giant BYoungPool™. The hue expresses the purity and energy of nature reinforced by the brand’s science-driven approach to skincare. This distinctive color identity reflects RIMAN’s positioning at the convergence of heritage ingredients and advanced research.

The uniquely textured cap surface draws inspiration from Jeju’s volcanic basalt, known for its natural filtration of Lava Energy Water. This tactile detail transcends decoration and symbolizes the brand’s origin and philosophy while strengthening its authentic connection to Jeju’s pristine environment.

Youngsu Hwang, Global Chief Sales Officer with RIMAN, commented: “As well as representing a design achievement, this award also validates our ingredient-centered philosophy and long-term commitment to integrating research, innovation, and brand identity. We will continue elevating RIMAN as a differentiated global K-beauty brand.”

The globally recognized iF DESIGN AWARD, presented by Germany’s iF International Forum Design GmbH, evaluates thousands of entries annually. The rigorous jury process assesses innovation, functionality, aesthetics, user experience, and sustainability. This recognition affirms RIMAN’s ability to compete at the highest international level, reflecting its commitment to science-driven research, proprietary ingredient innovation, and refined brand design.

RIMAN will continue investing in advanced research, sustainable product development, and elevated brand design to deliver meaningful beauty solutions worldwide, and reinforce its standing as a global leader in K-beauty.

For more information, please visit www.riman.com.

About RIMAN

Founded in 2018 in South Korea, RIMAN is a global beauty and wellness company redefining K-Beauty through Jeju heritage ingredients and advanced innovation. The company vertically manages the entire value chain — from raw material cultivation to product development — including its signature Giant BYoungPool™, a next-generation Centella asiatica cultivar protected by 20-year Plant Variety Protection (PVP) rights in both Korea and the United States.

Guided by its philosophy to deliver a difference people love, RIMAN creates innovative, trustworthy skincare and wellness solutions that empower individuals around the world to experience their most radiant selves.

CHIFENG, China, Feb. 27, 2026 /PRNewswire/ — Envision, a world-leading green technology company launched the first global shipment of green ammonia from Chifeng, Inner Mongolia to LOTTE Fine Chemical, a premier chemical company in South Korea. This shipment marks the world’s first end-to-end commercial delivery of green ammonia, encompassing the entire value chain from renewable hydrogen synthesis to international maritime logistics.

The cargo originates from Envision’s Chifeng facility, recognized as the world’s largest green hydrogen-ammonia production base. The park operates on the world’s most advanced 100% renewable power system, leveraging physical AI to intelligently orchestrate wind and solar energy into a stable supply for hydrogen and ammonia synthesis.

“This vessel carries more than just ammonia; it carries our commitment to a sustainable future,” said Yimin Lou, Senior Vice President and Chief Product Officer at Envision Energy. “By successfully launching this first vessel, Envision has proven that the green ammonia value chain is no longer just a blueprint—it is a reality. Leveraging Physical AI to harness the vast renewable resources of the Gobi Desert, we are now capable of delivering zero-carbon fuel to the world, starting with our partners in South Korea.”

Seung Won Chung, CEO of LOTTE Fine Chemical, stated, “The world’s first commercial introduction of green ammonia is drawing global attention beyond the company and national level. This milestone holds historic significance as the starting point for establishing the green hydrogen and ammonia value chain—considered a leading solution for the transition to carbon-free energy in response to the climate crisis.” He added, “We will continue to cooperate with global industry leaders to lay the foundation for becoming Asia’s No.1 clean ammonia hub.”

Now delivering 320,000 tons of green ammonia annually with exports commencing in Q4, 2025, Envision offers a proprietary, full-stack technology package for green hydrogen and ammonia production. By 2028, the industrial park is projected to produce 1.5 million tons of green ammonia per year, serving as a replicable model for clean industrial hubs worldwide.

Envision’s green ammonia has attained prestigious certifications and meets the most stringent industry standards, including the ISCC EU, ISCC PLUS, and RFNBO compliance. Furthermore, Envision leverages proprietary AI technology within its wind-to-hydrogen system to maximize the efficiency and reliability of the entire conversion process from wind power to green molecules.

During the World Economic Forum (WEF) 2026 in Davos, the project was featured as a flagship case study in the WEF white paper, “From Blueprint to Reality: Delivering a Stronger Business Case for Energy Infrastructure,” highlighting its role as a global benchmark for the zero-carbon industrial transition.

DeviceHub centralises Sennheiser devices in the cloud, combining remote monitoring, intuitive navigation, and built-in security to give teams a clearer, more efficient way to manage AV systems at scale

SINGAPORE, Feb. 26, 2026 /PRNewswire/ — Sennheiser today announced the launch of DeviceHub, a secure, cloud-based platform that gives organisations centralised visibility and control of their Sennheiser devices from anywhere in the world. Following extensive internal testing and a private beta phase, DeviceHub is now publicly available in beta, starting with support for TeamConnect Bar Solutions. 

Aligned with Sennheiser’s mission to make collaboration and learning easier, DeviceHub combines remote monitoring, clear oversight, and secure role-based access into one browser-based environment. The launch follows the platform’s initial announcement at InfoComm US in June 2025, marking the next step in a broader DeviceHub roadmap, with additional Sennheiser devices gaining compatibility throughout 2026.

“DeviceHub represents a major step forward in how customers manage their Sennheiser devices,” said Iain Horrocks, Product Marketing Manager, Software & Security, Sennheiser. “By bringing secure, cloud-based control to the entire ecosystem, we’re giving IT and AV teams the tools they need to work more efficiently, collaborate more effectively, and support better learning and meeting experiences…and this is just the beginning.” 

As a single cloud-based platform, DeviceHub makes management of networked Sennheiser devices accessible through any browser. Real-time monitoring, diagnostics, and alerts provide clear insight into device status and performance, helping teams act before issues disrupt meetings, classes, or collaboration spaces, whether on site or remotely.

For IT personnel, DeviceHub simplifies management at scale by organizing devices by room, building, campus, or region in a structure that mirrors real-world environments. This provides a clear view of every space from a single platform, allowing teams to navigate between locations easily, view devices in context, and understand system health at a glance, from a handful of rooms to global estates.

The platform enables teams to collaborate securely across an organization through role-based access, ensuring technicians, administrators, and integrators see and control only what they need, with access limited to the locations and systems relevant to their responsibilities. Support for modern authentication methods reinforces secure collaboration while keeping responsibilities clearly defined, workflows streamlined, and accountability transparent.

Built on Microsoft Azure, security and trust are built into DeviceHub from the start. The platform follows industry-recognised IT security standards across authentication, authorisation, encryption, and data handling. Ongoing evaluation and compliance oversight ensure DeviceHub meets the privacy and security expectations of enterprise and education environments.

Built to grow with an organisation’s needs, DeviceHub will support TeamConnect Bar Solutions at launch, with compatibility expanding across additional Sennheiser devices throughout 2026. A streamlined Local Web UI also supports efficient single-device setup through a browser, reducing software dependencies during installation.  The platform will continue to evolve with new capabilities that strengthen monitoring, configuration, and collaboration across the ecosystem.

Early customers have already provided feedback regarding their experience with DeviceHub, with Guillaume Amaurin, AV Specialist, Sainte-Justine Hospital, Quebec, sharing, “DeviceHub has significantly simplified the management of our infrastructure. A single configuration is enough to onboard a new device, making the onboarding process fast and frictionless. The portal is easy to access and is used daily by the entire team to configure the bars and monitor their usage, wherever we are.”

Alain Lamontagne IT Specialist, Sainte-Justine Hospital, Quebec, added, “Compared to the previous method based on Cockpit, which was limited to a single computer and required the bars to be re-added whenever the machine changed, DeviceHub represents a major gain in both time and flexibility. We are looking forward to being able to add more devices synchronized with the portal.”

Visit our DeviceHub product page to learn more.

About the Sennheiser Brand – 80 Years of Building the Future of Audio

We live and breathe audio. We are driven by the passion to create audio solutions that make a difference. This passion has taken us from the world’s greatest stages to the quietest listening rooms – and made Sennheiser the name behind audio that doesn’t just sound good: It feels true. In 2025, the Sennheiser brand celebrates its 80th anniversary. Since 1945, we stand for building the future of audio and bringing remarkable sound experiences to our customers.

While professional audio solutions such as microphones, meeting solutions, streaming technologies and monitoring systems are part of the business of Sennheiser electronic SE & Co. KG, the business with consumer devices such as headphones, soundbars and speech-enhanced hearables is operated by Sonova Holding AG under the license of Sennheiser.

www.sennheiser.com

www.sennheiser-hearing.com

SUZHOU, China, Feb. 27, 2026 /PRNewswire/ — Basecare Medical (02170.HK) has recently encountered a key catalyst——its Gems one-step embryo culture medium has officially obtained the China Class III Medical Device Registration Certificate (National Medical Products Administration Registration No. 20253180071). This represents a core signal of the company’s strategic transformation implementation and accelerated domestic substitution layout, and is expected to become an important driver for its valuation repair, warranting close attention.

From a market logic perspective, the approval of this product essentially serves as Basecare’s “entry ticket” into the vast blue ocean of the multi-billion-yuan assisted reproductive consumables market. The underlying product strength and market foundation determine the certainty of its subsequent performance delivery, which serves as the core starting point for our analysis of its investment value.

I. Product Strength: Backed by Internationally Mature Assets, Market Competitiveness Need Not Be Overly Concerning

Unlike the model of many domestic enterprises involving “R&D from scratch and long-term investment,” Basecare’s Gems culture medium was acquired as an internationally mature asset – a particularly crucial point. Its technology originates from world-leading assisted reproductive institutions, was developed under the guidance of the “Father of Culture Media,” has undergone 12 years of clinical validation, has helped bring tens of thousands of healthy babies into the world, and has received certifications from multiple regions including the US FDA, European CE, and Australian TGA. Its technological barriers are clear, placing it in the top tier of the industry.

First, R&D risk is eliminated. By acquiring a mature product directly, Basecare has bypassed years of R&D investment and the uncertainty of potential R&D failure, enabling rapid product implementation and market launch, thus shortening the performance delivery cycle. This is a significant advantage for a target with clear expectations for performance improvement.

Second, an existing market foundation is in place. This product was previously authorized for sale by COOK in China, where it has captured 40% of the domestic market share. This means its market acceptance has been fully validated. After Basecare takes over, it can rapidly achieve market penetration without needing to re-cultivate the market, converting the existing market share into its own revenue, providing clear support for performance increment.

Third, demand side exhibits rigidity. Clinical data shows that this product can increase the rate of high-quality embryos by 46%, effectively improving the pregnancy success rate for older couples and reducing miscarriage rates. With domestic demand for fertility at an advanced age continuously rising and the volume of assisted reproductive treatments growing steadily, hospitals’ rigid demand for high-quality consumables provides stable support for the product’s subsequent sales, mitigating concerns about demand falling short of expectations.

II. Industry Analysis: Domestic Substitution + Policy Dividends, Sector Prosperity Continues to Rise

“Sector prosperity” serves as a core dimension for assessing a target’s long-term value. The assisted reproduction sector in which Basecare operates is currently at the intersection of two major trends: “accelerated domestic substitution + release of policy dividends.” The industry’s prosperity is continuously rising, forming the core logic for its long-term investment value.

Previously, the domestic embryo culture medium market was long dominated by overseas giants, characterized not only by relatively high prices but also by supply shortage risks due to international supply chain fluctuations. The need for domestic substitution was urgent. The approval of Basecare’s related product marks a significant breakthrough in the domestic substitution of high-end embryo culture media, precisely aligning with the broader trend of domestic substitution for medical devices in China, offering inherent policy advantages.

Firstly, policy dividends are continuously increasing. The national level persistently promotes fertility support policies. The gradual inclusion of assisted reproductive technology in medical insurance and the implementation of childcare subsidies directly boost the volume of assisted reproductive treatments, thereby driving demand for related consumables. This provides clear policy support for Basecare’s product sales, ensuring a stable demand side for the industry.

Secondly, product competitiveness holds differentiated advantages. Compared to imported products, Basecare’s domestically produced version offers higher cost-effectiveness. It can also be paired with the company’s already approved supporting equipment, providing hospitals with a one-stop solution. This synergistic advantage can effectively enhance market competitiveness, accelerate the import substitution process, and seize market share from overseas giants.

Thirdly, revenue growth has clear expectations. Referring to the product’s previous sales performance in China, if fully rolled out subsequently, it is expected to bring stable revenue increments to Basecare, becoming a new engine for the company’s performance growth. This also serves as a core catalytic factor for short-term performance improvement.

III. Company Transformation: Full-Chain Layout Realized, Valuation Reassessment Holds Imaginative Potential

From the perspective of the company’s development logic, this product approval serves as a key marker of Basecare’s strategic transformation implementation. Previously, the company mainly focused on the preimplantation genetic testing (PGT) business, with a relatively single business scope and weaker risk resistance capability. Through the acquisition of relevant international brands, the company has successfully opened up the full-chain layout of “Testing + Equipment + Consumables,” completing its transformation from a single IVD (in vitro diagnostics) enterprise to a full-chain IVF service provider, further improving its business matrix.

Post-transformation, Basecare can not only provide testing services but also sell products such as embryo culture media and culture equipment. The business synergy is significant, effectively enhancing value per client. More crucially, currently, few domestic enterprises have achieved a full-chain layout in assisted reproduction. This differentiated positioning helps the company break free from the growth bottleneck of a single business and enhance its long-term competitiveness.

From a valuation logic perspective, an improved business structure helps reduce the operational risks associated with a single business, enhances the stability of the company’s profitability, and creates room for a re-evaluation of the company’s valuation. For long-term investors, this transformation towards a full-chain layout serves as a core manifestation of the company’s long-term development potential and a key support for subsequent valuation reassessment.

IV. Investment Analysis and Risk Warning: View Positive News Rationally, Beware of Volatility Risks

Based on the above analysis, the investment value assessment for Basecare Medical (02170.HK) is as follows: In the short term, the product approval serves as a clear positive catalyst. Coupled with the product’s high maturity and solid market foundation, short-term performance growth has a certain degree of certainty, which is expected to drive a valuation repair for the stock price. In the long term, the realization of the full-chain layout, the advancement of domestic substitution, coupled with rising industry prosperity, suggest the company has certain growth potential.

However, investors are reminded to remain rational. The realization of positive news does not necessarily equate to a stock price increase. Relevant risks still need to be monitored, with three key points to focus on:

1.  Performance Realization Risk: Post-approval, the progress of market promotion and customer expansion may fall short of expectations, leading to slower-than-expected revenue growth. This serves as the most critical risk to watch in the short term.

2.  Market Competition Risk: Overseas giants will not easily give up market share and may compete through price reductions, product upgrades, etc. If Basecare cannot achieve rapid market penetration, it may impact performance growth.

3.  Policy and Market Volatility Risk: The assisted reproduction industry is significantly influenced by policy changes. Adjustments to related policies could affect industry demand. Concurrently, the Hong Kong stock market itself is highly volatile; short-term positive news might be digested by market sentiment. Investors need to implement risk control measures.

Comprehensive Assessment: The approval of Basecare’s Gems one-step embryo culture medium represents a significant milestone in the company’s business development and a key step in its strategic transformation and domestic substitution layout. It aligns with the industry development trend and possesses certain investment merit. For small and medium investors, Basecare can be considered a key watchlist target in the assisted reproduction sector. In the long run, with the popularization of assisted reproduction inclusion in medical insurance and the increase in industry concentration, Basecare, as a leading enterprise in the upstream of the industrial chain, its technological barriers and the value of its full industrial chain layout are likely to be repriced by the market. The company’s valuation system stands at a critical juncture of reshaping. The current stock price does not fully reflect its potential in high-barrier technology platforms and future performance conversion, indicating significant room for value reassessment and appreciation.

SINGAPORE, Feb. 27, 2026 /PRNewswire/ — Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, announced today that Clarity II, its dual-wavelength long-pulse laser platform, has received regulatory approval in China and Japan. This marks a significant expansion of the company’s clinically approved laser portfolio across two of Asia’s most highly regulated aesthetic markets. 

“The approval enables the introduction of a single, integrated dual wavelength laser platform designed to support multiple treatment indications and diverse patient profiles and is also reflective of Cynosure Lutronic’s growing strength across the Asia Pacific region” said Nadav Tomer, CEO of Cynosure Lutronic.

China: Regulatory Approval 

In China, Clarity II (marketed as CLARITY II ICD) has received regulatory approval for use in medical institutions as of 12^th February 2026.  

• Product Name: Clarity II ICD 
• Approved Indications: 
• 755nm laser – approved to reduce wrinkles on the cheeks 
• 1064nm laser – approved to reduce unwanted body hair 

The approval authorizes the use of a single integrated platform across multiple treatment applications within regulated clinical settings of China. 

Japan: Regulatory Approval 

In Japan, Clarity II has received regulatory clearance as of 9^th January 2026 for use in medical aesthetic practices. 

• Product Name: Clarity II 
• Approved Indication: 
• Alexandrite 755nm / Nd:YAG 1064nm approved for Long-term hair reduction 

The clearance confirms compliance with Japan’s stringent medical device regulatory requirements for laser-based aesthetic treatments. 

Clinical and Operational Context 

In both China and Japan, medical aesthetic practices are operating under increasingly rigorous regulatory and clinical expectations, with heightened emphasis on treatment precision, indication-specific use, and safety. 

The regulatory approvals of Clarity II reflect growing demand for laser platforms that consolidate multiple clinically validated applications within a single system, while maintaining strict control over energy delivery and treatment parameters. In China, approval across both hair removal and wrinkle treatment applications enables practitioners to address multiple patient needs with one versatile platform. In Japan, clearance of the latest-generation system reinforces confidence in technological refinement and output consistency within a highly regulated clinical environment. 

Together, these approvals position Clarity II as a platform aligned with the evolving standards of advanced aesthetic practice in Asia compliance, and clinical versatility are increasingly critical. 

About Clarity II 

Clarity II is a dual-wavelength long-pulse laser system designed to support a range of aesthetic medical applications. The platform integrates: 

• Alexandrite 755nm and Nd:YAG 1064nm wavelengths in a single system 
• Large spot sizes to support efficient treatment of broad areas 
• Short pulse duration capabilities for refined and precision-based treatments 
• A fiber-free system architecture designed to simplify operation and maintenance 
• Automated delivery features intended to support consistency and practitioner workflow 

About Cynosure Lutronic 

Cynosure Lutronic was formed following the merger of Cynosure and Lutronic in 2024 which creates a global medical aesthetics organization built on more than 60 years of combined innovation in energy-based technologies. 

Cynosure Lutronic develops and commercializes energy-based devices across a wide range of aesthetic indications with direct operations in North America, Europe, and Asia-Pacific, and product distribution in approximately 130 countries. 

LinkedIn | Instagram